These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 3689664)

  • 21. Treatment of hypercalcemia of malignancy with intermittent single infusions of 3-amino-1-hydroxypropylidene-1, 1-biphosphonate (APD).
    Rischin D; Bishop JF
    Aust N Z J Med; 1988 Aug; 18(5):736-7. PubMed ID: 3245828
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.
    van Breukelen FJ; Bijvoet OL; Frijlink WB; Sleeboom HP; Mulder H; van Oosterom AT
    Calcif Tissue Int; 1982 Jul; 34(4):321-7. PubMed ID: 6814719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia.
    Body JJ; Louviaux I; Dumon JC
    Support Care Cancer; 2000 Sep; 8(5):398-404. PubMed ID: 10975689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. No effect of APD (amino hydroxypropylidene bisphosphonate) on hypercalcemia in patients with renal osteodystrophy.
    Hené RJ; Visser WJ; Duursma SA; Raymakers JA; de bos Kuil RJ; Dorhout Mees EJ
    Bone; 1990; 11(1):15-20. PubMed ID: 2331426
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
    van Holten-Verzantvoort AT; Bijvoet OL; Cleton FJ; Hermans J; Kroon HM; Harinck HI; Vermey P; Elte JW; Neijt JP; Beex LV
    Lancet; 1987 Oct; 2(8566):983-5. PubMed ID: 2889957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy.
    Purohit OP; Radstone CR; Anthony C; Kanis JA; Coleman RE
    Br J Cancer; 1995 Nov; 72(5):1289-93. PubMed ID: 7577484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia.
    Body JJ; Pot M; Borkowski A; Sculier JP; Klastersky J
    Am J Med; 1987 May; 82(5):957-63. PubMed ID: 3578365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immobilization-related hypercalcaemia--a possible novel mechanism and response to pamidronate.
    Gallacher SJ; Ralston SH; Dryburgh FJ; Logue FC; Allam BF; Boyce BF; Boyle IT
    Postgrad Med J; 1990 Nov; 66(781):918-22. PubMed ID: 2267202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
    Reitsma PH; Bijvoet OL; Potokar M; van der Wee-Pals LJ; van Wijk-van Lennep MM
    Calcif Tissue Int; 1983 May; 35(3):357-61. PubMed ID: 6871766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An audit of the management of malignant hypercalcaemia.
    Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
    Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy.
    Wimalawansa SJ
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):591-5. PubMed ID: 7828347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pamidronate in the treatment of tumor-associated hypercalcemia].
    Pecherstorfer M; Janisch S; Marosi C; Wogritsch C; Bosse C; Schratzberger W; Gerber E; Fortelny A; Lenzhofer R; Rainer H
    Klin Wochenschr; 1991 Oct; 69(15):690-5. PubMed ID: 1795492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD).
    Ling PJ; A'Hern RP; Hardy JR
    Br J Cancer; 1995 Jul; 72(1):206-9. PubMed ID: 7599053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
    Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
    Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
    Fitton A; McTavish D
    Drugs; 1991 Feb; 41(2):289-318. PubMed ID: 1709854
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).
    Coleman RE; Woll PJ; Miles M; Scrivener W; Rubens RD
    Br J Cancer; 1988 Nov; 58(5):621-5. PubMed ID: 3219273
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of aminohydroxypropylidene diphosphonate in the treatment of malignancy-associated hypercalcaemia.
    Stevens MJ
    Med J Aust; 1987 Mar; 146(5):261-4. PubMed ID: 3821622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.